← Leaderboards
Sandy Hinckley
Quralis Corporation
$831,702
Attributed
$1,081,695
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $857.6K · FY2019–20$1M$750K$500K$250K$0
'19
'20
Funding mix
By agency
NIH$1,081,695 · 3
By mechanism
R44$857,576 · 2
R43$224,119 · 1
Top collaborators
- Daniel Elbaum1 shared
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseLeadFunctional DisorderNeurodegenerative DisordersMedicalMotor NeuronsNerve DegenerationInduced Pluripotent Stem CellAmyotrophic Lateral SclerosisBaseLinkIn VivoLengthAutophagocytosisGenetic TranscriptionLoss Of FunctionFutureDrug KineticsGenesDiagnosisFamilial Amyotrophic Lateral SclerosisDetectionCellsAls Patients
Grant awards (3)
Preclinical development of a Stathmin-2 splicing modulator for ALS$499,987
R44 · FY2020 · NS · contact PI
Development of a therapeutic Kv7 opener to restore motor excitability in ALS$357,589
R44 · FY2020 · NS · contact PI
Development of a human cellular TBK1 model for drug discovery in ALS$224,119
R43 · FY2019 · NS · contact PI